Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and/or direct pharmacodynamic effect?

about

Combination of Aflibercept and Bromfenac Therapy in Age-Related Macular Degeneration: A Pilot Study Aflibercept and Bromfenac in AMD.

P2860

Q36395332-05AA4E1D-DC84-48FD-9518-7FFD234C7AEB

P2860

Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and/or direct pharmacodynamic effect?

Item

http://www.wikidata.org/entity/Q40990867

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Ischaemic stroke after exposur ...... direct pharmacodynamic effect?

@en

type

Item

label

Ischaemic stroke after exposur ...... direct pharmacodynamic effect?

@en

prefLabel

Ischaemic stroke after exposur ...... direct pharmacodynamic effect?

@en

P1476

Ischaemic stroke after exposur ...... direct pharmacodynamic effect?

@en

P2093

E Civade

http://www.w3.org/2001/XMLSchema#string

H Bagheri

http://www.w3.org/2001/XMLSchema#string

J C Quintyn

http://www.w3.org/2001/XMLSchema#string

J Thorel

http://www.w3.org/2001/XMLSchema#string

J-L Montastruc

http://www.w3.org/2001/XMLSchema#string

P Cestac

http://www.w3.org/2001/XMLSchema#string

P2860

The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis.

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

Flow effects on coagulation and thrombosis.

Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.

Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration.

What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?

Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF.

Neovascular age-related macular degeneration and the risk of stroke: a 5-year population-based follow-up study.

Safety in Aflibercept versus Ranibizumab.

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.

P304

477-479

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCPT.12278

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25930164

http://www.w3.org/2001/XMLSchema#string

P921

vitamin K

Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and/or direct pharmacodynamic effect?

about

P2860

P2860

Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and/or direct pharmacodynamic effect?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921